Novogen updated investors on the company’s strategic review of operations. On June 8, 2017, Iain Ross was appointed as chairman, which triggered the review by the board and management team.
Lexington, Mass.-based Agenus quietly filed with the U.S. Securities and Exchange Commission (SEC) that it was halting the company’s clinical trial of its cancer vaccine Prophage.
Concerted effort by governments, regulators, and industry is rapidly expanding development of new therapies for the more than 7,000 known rare diseases.
NovoCure Ltd said its lead cancer therapy improved survival rate in brain cancer patients in combination with Avastin in a late-stage study, sending its shares up 23 percent in extended […]
New data from a midstage trial show that Celldex Therapeutics Inc’s experimental brain cancer vaccine, combined with standard therapy, continues to improve chances of survival for patients with recurrent cancer. […]
Lawrenceville, N.J.-based Celsion Corporation (CLSN) announced today that it completed the integration of its June 2014 acquisition of EGEN, Inc., and as part of the consolidation, had cut 15 to […]